Crizotinib (PF-02341066) is approved for the treatment of non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL), which harbor the fusion oncogenes EML4-ALK and NPM-ALK, respectively [9, 10]. This evidence concerns the gene NPM1 and anaplastic large cell lymphoma.